Live Breaking News & Updates on லிவர்பூல் அறிவியல் பூங்கா கண்டுபிடிப்பு மையம்

 
 
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces its unaudited interim results for the six months ended 30 September 2020.
 
·
Dr Huw Jones appointed as Chief Executive Officer
·
Completion of first out-licensing deal with Juvenescence for use of Sulforadex® technology in non-pharmaceutical markets. Up to $10.5m receivable in milestones with royalties on sales
·
Phase IIb/III trial using SFX-01 for
acute respiratory distress syndrome (
ARDS ) including COVID-19 patients sponsored by Dundee University, with grant funding from LifeArc; the STAR trial (
SFX-01 treatment for acute respiratory infections)
·
Patient recruitment commenced in STAR trial post the period end with data potent ....

United Kingdom , Borough Of Cheshire East , City Of , United Kingdom General , Evgen Pharmaplcwww , Barry Clarehuw Jones , Huw Jones , Evgen Pharma , Brownlow Hill , Geoff Nash Teddy Whiley , Richard Moulson , Paul Mcmanus Anna Dunphy , Juvenescence Ltd , Company Share Capital , International Financial Reporting Standards , London Stock Exchange , University Of Manchester , Market Of The London Stock Exchange , University Of Dundee , Liverpool Science Park Innovation Centre , Registrar Of Companies , European Union , Cancer Research United Kingdom Manchester Institute , Dundee University , Chief Executive , Chief Executive Officer ,